Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose-rate fractionated ALA-PDT for premalignant vulvar disorders
NL-OMON47821Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2013
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 5-aminolevulinic acid, clobetasol and imiquimod in Kraurosis vulvae and HPV-related vulvar intraepithelial neoplasia (4 arms), sponsored by Erasmus MC. Primary endpoints: Clinical response in VLS, Histological regression in VLS and 4 more. Started Jun 2013; status: active, not recruiting.
02
Drugs
5-aminolevulinic acidclobetasolimiquimod
03
Conditions
Kraurosis vulvaeHPV-related vulvar intraepithelial neoplasia
Beyond the preview
Go deeper on NL-OMON47821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47821.